Sarepta Therapeutics' (SRPT) Overweight Rating Reiterated at Cantor Fitzgerald

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "overweight" rating reissued by Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They currently have a $163.00 price objective on the biotechnology company's stock. Cantor Fitzgerald's target price points to a potential upside of 119.97% from the company's previous close.

Several other equities analysts have also commented on SRPT. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research report on Wednesday, November 27th. StockNews.com downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Royal Bank of Canada dropped their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a research note on Tuesday, February 11th. They issued a "hold" rating and a $136.00 target price for the company. Finally, Scotiabank started coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They set a "sector perform" rating and a $105.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $167.41.

Remove Ads

Sarepta Therapeutics Stock Up 0.9 %

Shares of SRPT stock traded up $0.65 during trading hours on Tuesday, reaching $74.10. 2,591,321 shares of the company's stock were exchanged, compared to its average volume of 1,215,931. Sarepta Therapeutics has a fifty-two week low of $73.05 and a fifty-two week high of $173.25. The stock's 50 day moving average is $107.19 and its 200-day moving average is $118.11. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market cap of $7.19 billion, a price-to-earnings ratio of 59.28 and a beta of 0.79.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Sarepta Therapeutics by 21.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,700 shares of the biotechnology company's stock valued at $212,000 after purchasing an additional 300 shares during the period. Oppenheimer Asset Management Inc. lifted its stake in Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company's stock valued at $557,000 after buying an additional 145 shares in the last quarter. Huntington National Bank boosted its holdings in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after buying an additional 175 shares during the last quarter. CIBC Asset Management Inc increased its stake in Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock worth $339,000 after buying an additional 86 shares in the last quarter. Finally, Commerce Bank raised its holdings in shares of Sarepta Therapeutics by 15.7% during the third quarter. Commerce Bank now owns 2,016 shares of the biotechnology company's stock valued at $252,000 after acquiring an additional 274 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.